GlassScriptPhysician profile
Peter T Gotsis
NPI 1760654750
$7,338.60
in general payments reported to CMS, 2019-2025
37 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $630 · 2021: $1,109 · 2022: $1,076 · 2023: $668 · 2024: $1,404 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.13 | 2021-2025 | |
| Novo Nordisk INC | $1,113.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $856.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $590.99 | 2019-2025 | |
| Lilly USA, LLC | $364.41 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $336.18 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.42 | 2019-2025 | Ofev, Jardiance |
| Biohaven Pharmaceuticals, INC. | $292.24 | 2021 | |
| Merck Sharp & Dohme LLC | $250.44 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $235.95 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.46 | 2022 | |
| Astellas Pharma US INC | $136.77 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $135.73 | 2019-2022 | |
| Exact Sciences Corporation | $123.58 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $122.78 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $105.88 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $103.82 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $100.47 | 2024-2025 | Spravato |
| Amgen INC. | $87.00 | 2019-2025 | Repatha, Otezla |
| Allergan, INC. | $85.75 | 2019-2020 | |
| Horizon Therapeutics Plc | $82.44 | 2022 | |
| Genentech USA, INC. | $28.15 | 2020 | |
| Amarin Pharma, INC. | $27.64 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.24 | 2019 | |
| Kyowa Kirin, INC. | $22.58 | 2025 | |
| Dexcom, INC. | $20.86 | 2025 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $20.57 | 2023 | |
| Scpharmaceuticals INC. | $19.51 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.14 | 2019 | |
| Dynavax Technologies Corporation | $16.81 | 2022 | |
| Noven Therapeutics, LLC | $16.29 | 2025 | Xelstrym |
| Lundbeck LLC | $15.14 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $14.58 | 2019 | |
| Phadia US INC. | $13.78 | 2021 | |
| Shire North American Group INC | $13.53 | 2019 | |
| Cranial Technologies, INC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gotsis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.